Stada and alvotech receive positive chmp opinion for europe's first ustekinumab biosimilar to stelara

Partners stada and alvotech today announced that the committee for medicinal products for human use (chmp) within the european medicines agency's (ema) has adopted a positive opinion for uzpruvo (avt04), a biosimilar candidate to stelara® (ustekinumab).
ALVO Ratings Summary
ALVO Quant Ranking